קונבריזה - Conbriza

קונבריזה - Conbriza
התוויות	CONBRIZA is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established. When determining the choice of CONBRIZA or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefit "

מידע ברשת

קונבריזה - Conbriza


מרכיב פעיל	Bazedoxifene
קבוצה פרמקולוגית (ATC)	"Selective estrogen receptor modulators"
שם התרופה	"קונבריזה®" (קישור לדף התרופה במאגר משרד הבריאות)
סל הבריאות	כלול
מסגרת הכללה בסל	עדכון סל התרופות 2013 טיפול באוסטיאופורוזיס
התוויות	CONBRIZA is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established. When determining the choice of CONBRIZA or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefit "
שם יצרן	Pfizer Ireland Pharmaceuticals
שם בעל הרישום	Neopharm Ltd